Skip to content

Study · Non-randomized trial · n = 11 · 2005

6 results

The histrelin implant: a novel treatment for central precocious puberty.

Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, Gelber H, Spitz IM

Pediatrics1 Dec 2005Cited by 38 (Europe PMC)

PMID16322137 (opens in a new tab)DOI10.1542/peds.2005-0538 (opens in a new tab)PepBankPUB-16322137
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In girls with central precocious puberty, histrelin implant treatment accompanied breast regression, decreased growth velocity, and slower bone-age advancement.

    In plain wordsIn girls with central precocious puberty, breast development regressed, growth slowed, and bone age advanced more slowly during histrelin treatment.

    Peptide
    Histrelin
    Outcome
    DecreaseBreast development, growth velocity, and bone-age advancement
    Study

    n = 11

    Outcome group
    Pubertal Development · Endocrine and hormones
    Studied dose
    average release rate of 65 microg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In all girls, breast development regressed, growth velocity decreased, and bone-age advancement was slowed.
    3 context sentences
    Summary · context
    Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 microg/day.
    Summary · context
    We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression.
    Summary · context
    All subjects were initially treated with depot intramuscular GnRHa triptorelin embonate. Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued.
  2. 02HumanNon-randomized trialEfficacy outcome

    In girls with central precocious puberty, basal gonadotropins, stimulated gonadotropin responses, and estradiol levels were suppressed during histrelin implant treatment.

    In plain wordsIn girls with central precocious puberty, basal and stimulated puberty hormones and estradiol were suppressed during histrelin implant treatment.

    Peptide
    Histrelin
    Outcome
    DecreaseBasal and stimulated gonadotropins and estradiol
    Study

    n = 11

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    average release rate of 65 microg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Basal gonadotropins and their responses to GnRH-STs and E2 levels were suppressed.
    3 context sentences
    Summary · context
    Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 microg/day.
    Summary · context
    We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression.
    Summary · context
    All subjects were initially treated with depot intramuscular GnRHa triptorelin embonate. Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued.
  3. 03HumanNon-randomized trialEfficacy outcome

    In girls with central precocious puberty, peak stimulated luteinizing hormone decreased from 1.30 ± 1.34 before histrelin insertion to 0.25 ± 0.08 mIU/mL at 9 months.

    In plain wordsIn girls with central precocious puberty, stimulated luteinizing hormone was lower at nine months than before histrelin implant insertion.

    Peptide
    Histrelin
    Outcome
    DecreasePeak stimulated luteinizing hormone at 9 months
    Study

    n = 11

    Comparator
    Before implant insertion during depot GnRHa treatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    average release rate of 65 microg/day · subcutaneousAs given in this study (human).

    Measurements

    Peak luteinizing hormone
    1.3 mIU/mL
    preinsertion
    Peak luteinizing hormone
    0.25 mIU/mL
    9 months

    Source sentences

    Summary
    Peak luteinizing hormone and follicle-stimulating hormone responses to GnRH-STs at preinsertion versus 9 months were 1.30 +/- 1.34 vs 0.25 +/- 0.08 and 1.68 +/- 1.08 vs 1.13 +/- 0.55 mIU/mL, respectively.
    3 context sentences
    Summary · context
    Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 microg/day.
    Summary · context
    We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression.
    Summary · context
    All subjects were initially treated with depot intramuscular GnRHa triptorelin embonate. Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued.
  4. 04HumanNon-randomized trialEfficacy outcome

    In girls with central precocious puberty, peak stimulated follicle-stimulating hormone decreased from 1.68 ± 1.08 before histrelin insertion to 1.13 ± 0.55 mIU/mL at 9 months.

    In plain wordsIn girls with central precocious puberty, stimulated follicle-stimulating hormone was lower at nine months than before histrelin implant insertion.

    Peptide
    Histrelin
    Outcome
    DecreasePeak stimulated follicle-stimulating hormone at 9 months
    Study

    n = 11

    Comparator
    Before implant insertion during depot GnRHa treatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    average release rate of 65 microg/day · subcutaneousAs given in this study (human).

    Measurements

    Peak follicle-stimulating hormone
    1.68 mIU/mL
    preinsertion
    Peak follicle-stimulating hormone
    1.13 mIU/mL
    9 months

    Source sentences

    Summary
    Peak luteinizing hormone and follicle-stimulating hormone responses to GnRH-STs at preinsertion versus 9 months were 1.30 +/- 1.34 vs 0.25 +/- 0.08 and 1.68 +/- 1.08 vs 1.13 +/- 0.55 mIU/mL, respectively.
    3 context sentences
    Summary · context
    Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 microg/day.
    Summary · context
    We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression.
    Summary · context
    All subjects were initially treated with depot intramuscular GnRHa triptorelin embonate. Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued.
  5. 05HumanNon-randomized trialEfficacy outcome

    In six girls with central precocious puberty, basal and stimulated gonadotropins and estradiol remained suppressed 15 months after histrelin implant insertion.

    In plain wordsIn six girls with central precocious puberty, puberty hormones and estradiol remained suppressed 15 months after histrelin implant insertion.

    Peptide
    Histrelin
    Outcome
    DecreaseMaintained gonadotropin and estradiol suppression at 15 months
    Study

    n = 6

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    average release rate of 65 microg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Basal and stimulated gonadotropin levels and E2 level remained suppressed in all 6 patients followed for 15 months after implant insertion.
    3 context sentences
    Summary · context
    Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 microg/day.
    Summary · context
    We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression.
    Summary · context
    All subjects were initially treated with depot intramuscular GnRHa triptorelin embonate. Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued.
  6. 06HumanNon-randomized trialOther

    In girls with central precocious puberty, patients and parents reported less pain, discomfort, and school and work interference with histrelin implants than monthly injections.

    In plain wordsPatients and parents reported less pain, discomfort, and school and work interference with histrelin implants than monthly injections.

    Peptide
    Histrelin
    Outcome
    DecreasePain, discomfort, and interference with school activity and work
    Study

    n: not reported in source

    Comparator
    Standard monthly injections
    Outcome group
    Quality of life · Whole body
    Studied dose
    average release rate of 65 microg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients and parents reported less pain and discomfort and less interference with school activity and work with the implant compared with standard monthly injections.
    3 context sentences
    Summary · context
    Recently, a subcutaneous implant was developed that releases the GnRHa histrelin at an average rate of 65 microg/day.
    Summary · context
    We studied 11 girls with CPP to determine if the histrelin implant can maintain long-term gonadotropin suppression.
    Summary · context
    All subjects were initially treated with depot intramuscular GnRHa triptorelin embonate. Implants were inserted subcutaneously under local anesthesia, and depot GnRHa treatment was discontinued.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.